SEP-174559, formerly known as (S)-Desmethylzopiclone and (S)-DMZ, is a gamma-aminobutyric acid (GABA) receptor agonist potentially for the treatment of anxiety and muscle spasticity. Micromolar concentrations of SEP-174559 potentiated GABA(A) receptor currents evoked by subsaturating concentrations of GABA. The potentiation was related to a leftward shift in the GABA dose-response curves, suggesting the drug acts to increase GABA binding affinity. SEP-174559 and its parent compound, racemic zopiclone, were not selective between alpha1-, alpha2-, or alpha3-bearing GABA(A) receptors. SEP-174559 did not affect serotonin type-3 receptor function but was found to inhibit nicotinic acetylcholine (nACh) receptors. SEP-174559 inhibited N-methyl-D-aspartate (NMDA) receptor currents but did not affect non-NMDA receptors. References: de Albuquerque NC, de Gaitani CM, de Oliveira AR. A new and fast DLLME-CE method for the enantioselective analysis of zopiclone and its active metabolite after fungal biotransformation. J Pharm Biomed Anal. 2015 May 10;109:192-201. doi: 10.1016/j.jpba.2015.02.039. PubMed PMID: 25778930.

纯度：≥98%

CAS：151776-26-0